** Shares of Massachusetts-based gene-editing firm Intellia Therapeutics NTLA.O up 8.4% at $11.71
** Company posts Q4 collaboration revenue of $12.9 million, beating analysts' estimates of $8.5 million, according to data compiled by LSEG
** Company's sales was mainly driven by collaboration revenue received under the Regeneron REGN.O agreements to develop gene-editing therapies for neurological and muscular disease
** Brokerage Leerink Partners expects shares to rise in the mid-single digits as company fleshed out details including operating expenses on call; NTLA expects 5%-10% lower operating expenses vs a year ago
** NTLA also expects operating expense below 2024 levels for the next several years as R&D spend sunsets with enrollment completion/trial conclusions in 2026 and beyond
** Company plans to submit a marketing application for a rare genetic disorder therapy, NTLA-2002, in H2 2026 to a potential U.S. launch in 2027
** "NTLA-2002 remains the most underappreciated asset in our coverage universe heading into upcoming pivotal (trial) data," brokerage says
** NTLA fell 61% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.